Top Markets
Coin of the day
IMBdx IMBdx

IMBdx

461030
Rank in Stocks #27750
IMBdx, Inc. specializes in developing advanced liquid biopsy technologies for... IMBdx, Inc. specializes in developing advanced liquid biopsy technologies for cancer detection and management. The company's core mission revolves around three key areas: facilitating the diagnosis and treatment strategies for advanced-stage cancers, enabling the early identification of cancer recurrence after surgical interventions, and providing solutions for the early diagnosis of cancer. Its notable product offerings include AlphaLiquid, CancerDetect, and CancerFind. The firm was established by Tae-Yu Kim, Sung-Tae Moon, and Doo-Hee Bang on July 5, 2018, and maintains its headquarters in Seoul, South Korea.
Share Price
$2.15
Market Cap
$30.83M
Change (1 day)
0.81%
Change (1 year)
-61.85%
Country
KR
Trade IMBdx (461030)

Category

Revenue for IMBdx (461030)
Revenue in Aug 2026 TTM: 0
According to IMBdx latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for IMBdx from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
$12.62B -
US
$2.23B -
US
$6.02B -
NL
$15.70B -
AU
- -
CH